Alvotech And DKSH Extend Partnership For Six Biosimilars
Aim To Target Emerging Asian Markets
Executive Summary
Alvogen sister company Alvotech is continuing to extend its network of commercial partners by expanding its partnership with DKSH, a Swiss market expansion services group, for the commercialization of six biosimilars in Asian markets.
You may also be interested in...
Hyphens Pharma Bags Rights To Stelara Rival
Hyphens Pharma has struck a licensing deal with DKSH’s Favorex to secure rights to Alvotech’s proposed ustekinumab rival to Stelara in Singapore, Malaysia and the Philippines.
Alvotech And Cipla Expand Biosimilars Deal For Australia And New Zealand
Cipla has expanded its partnership with Alvotech to cover the commercialization of four biosimilars in Australia and New Zealand, building on an existing alliance covering South Africa and emerging markets.
Partnerships Provide Global Foundation For Alvotech
A network of marketing deals with key players across the globe has laid the foundations for Alvotech’s biosimilars to be marketed worldwide, the company’s founder and chairman tells Generics Bulletin in an exclusive interview.